Free cognitive restructuring worksheet: A therapist’s guide (PDF)
Download your free cognitive restructuring worksheet Cognitive restructuring wor...
Last Updated: July 27, 2026
Key Takeaways
The alexithymia test is a standardized self-report measure assessing difficulty identifying, describing, and processing emotions.
The most widely used validated instrument is the Toronto Alexithymia Scale (TAS-20), a 20-item questionnaire with three clinical subscales measuring emotional awareness.
Alexithymia screening helps clinicians identify emotion-processing difficulties that underlie anxiety, depression, somatic complaints, and interpersonal conflict.
Practice management software like Pabau lets clinicians send structured intake questionnaires, capture responses in the patient record, and fold the findings into care planning.
Download your free alexithymia test (PDF)
A standardized psychological assessment tool evaluating an individual’s ability to identify, understand, and express emotions. Includes 20-item format with three subscales measuring difficulty identifying feelings, difficulty describing feelings, and externally oriented thinking.
Download templateAn alexithymia test is a short self-report questionnaire that measures how much difficulty someone has identifying, describing, and processing emotions. This guide covers how to run one in your mental health practice, how to score the most-used version (the Toronto Alexithymia Scale, TAS-20), and how to turn the result into a treatment plan. You can download the free test above and hand it to patients at intake.
What is the alexithymia test?
Alexithymia literally means “without words for emotion.” It describes a profile marked by difficulty identifying feelings, reduced ability to describe emotional states, and an externally focused thinking style. The alexithymia test is a standardized self-report instrument that measures these three dimensions.
The Toronto Alexithymia Scale (TAS-20)
The most widely used tool is the Toronto Alexithymia Scale (TAS-20), developed by Bagby, Parker, and Taylor at the University of Toronto. It comprises 20 items rated on a 5-point Likert scale, generating a total score and three subscale scores: Difficulty Identifying Feelings (DIF), Difficulty Describing Feelings (DDF), and Externally Oriented Thinking (EOT).
Other alexithymia questionnaires
The Perth Alexithymia Questionnaire (PAQ) is a validated 24-item measure that scores positive and negative emotions separately. The 37-item Online Alexithymia Questionnaire (OAQ-G2) is popular for self-screening online, though it is less formally validated than the TAS-20 or PAQ. Each has distinct psychometric properties and clinical uses.
How to use the test in clinical practice
Deploying an alexithymia test in your practice follows a structured five-step workflow:
- Introduce during intake. Frame the alexithymia test as part of routine emotional awareness screening. Explain to the patient: “This short questionnaire helps us understand how you process and describe feelings. Your honest answers guide our treatment.”
- Administer the self-report form. Provide the TAS-20 or equivalent in paper or digital format via digital intake forms that streamline questionnaire collection. Allow 5-10 minutes for completion.
- Score the responses. Calculate the DIF, DDF, and EOT subscale totals, then sum for an overall score. TAS-20 total scores range from 20 (lowest) to 100 (highest). A score of 61 or higher suggests clinically significant alexithymia.
- Document the result. Record the total score and subscales in the patient record. Highlight elevated subscales (e.g., “DIF elevated, suggests difficulty naming emotions”).
- Integrate into treatment planning. Use the findings to guide psychoeducation, emotion-regulation skill building, and progress tracking with standardized forms.
In practice management software like Pabau, patients complete the questionnaire as a digital intake form that saves straight to their record, and Pabau Scribe, our AI scribe, drafts the clinical summary. That takes the manual data entry off your team.
Who benefits from the test?
The alexithymia test benefits clinicians across multiple mental health and medical specialties:
- Therapists and counselors. Assess baseline emotional awareness in clients presenting with depression, anxiety, or relational difficulties. Alexithymia often co-occurs with trauma-related dissociation.
- Psychiatrists and psychiatric nurses. Identify emotion-processing barriers in patients with somatic symptom disorder, panic, or medication-resistant mood conditions.
- Primary care and functional medicine practitioners. Screen for alexithymia in patients with medically unexplained symptoms, chronic pain, or functional GI complaints.
- Occupational therapists and speech-language pathologists. Assess interoceptive awareness deficits in neurodivergent clients (autism, ADHD) for whom emotional identification difficulty impacts social communication.
- Group and multi-provider practices. Run screening as a standardized intake protocol, with results tracked across visits in psychiatry EMR software.
Benefits of routine screening
Systematic alexithymia screening strengthens clinical outcomes and practice efficiency.
Early identification: Detecting alexithymia traits during intake reveals hidden barriers to therapeutic engagement. Patients with high alexithymia may struggle to report mood shifts or connect emotions to bodily sensations. Knowing this upfront shapes how you approach the work.
Personalized treatment. Subscale patterns guide the intervention. High DIF (difficulty identifying feelings) points to emotion-labeling exercises. High DDF (difficulty describing feelings) responds to narrative therapy or somatic work. High EOT (externally oriented thinking) suggests mindfulness training.
Objective tracking. Serial alexithymia testing across therapy episodes documents emotional awareness improvement. Patient care workflows integrating structured questionnaires create an auditable record of progress for clinician accountability and burnout prevention.
Compliance and risk reduction. Standardized clinical forms for emotional assessment satisfy documentation requirements for clinical supervision, insurance authorization, and accreditation standards.
Pro Tip
Pair alexithymia screening with somatic assessment tools (body sensation checklists, interoception exercises) to build patients’ awareness of emotion-sensation links. This dual approach accelerates emotional literacy development and improves therapeutic alliance.
Alexithymia and autism: overlapping yet distinct
A common clinical question: Is alexithymia autism? The short answer is no, though the two frequently co-occur.
Alexithymia is a specific difficulty with emotion identification and expression. Autism is a neurodevelopmental condition affecting communication, social interaction, and sensory processing. An autistic person may have typical emotional awareness but express it differently, through literal speech or unconventional timing. A non-autistic person, by contrast, may have profound alexithymia with a typical social presentation.
Research suggests alexithymia is more common in autistic adults, possibly because autism involves reduced interoceptive feedback or different emotion-processing neurology. Running the test with neurodivergent patients clarifies whether the difficulty stems from autism, co-occurring alexithymia, or both, which shapes the support you offer.
Interpreting the scores
TAS-20 interpretation follows clinical thresholds developed across normative samples:
- 20-51: No significant alexithymia. Patient demonstrates typical emotional awareness and expressiveness.
- 52-60: Borderline alexithymia. Some difficulty naming or describing emotions, but not clinically impaired.
- 61-100: Significant alexithymia. Marked difficulty identifying, describing, or processing emotions warrants psychoeducation and targeted intervention.
Subscale analysis reveals specific deficits. A patient with high DIF but low DDF identifies feelings poorly yet can articulate them once named. The reverse pattern, high DDF with low DIF, shows intact feeling recognition but poor verbal expression. Psychology practice software that stores the subscale scores in the record lets you see these patterns at a glance and track them across visits.
Clinical note: The alexithymia test is a screening tool, not a diagnostic instrument. Elevated scores warrant further assessment (clinical interview, standardized measures of emotion regulation, neurodevelopmental screening) before treatment planning.
Conclusion
The alexithymia test is an efficient screening tool that surfaces emotion-processing barriers early in care. Built into routine intake, it gives you objective baseline data to personalize treatment, track progress, and show improvement over time. Book a demo to see how Pabau turns intake questionnaires into documented results inside the patient record.
Continue your research
Need a framework for emotion-regulation skill building? Psychiatric evaluation template provides structured assessment domains for documenting emotional and behavioral history alongside alexithymia screening.
Looking to streamline patient intake workflows? Client record features store assessment results, subscale scores, and clinical summaries in a unified patient profile.
Want to automate documentation after assessment? AI-powered scribe tools generate clinical summaries of alexithymia findings and treatment recommendations in seconds.
Frequently asked questions
What is an alexithymia test?
An alexithymia test is a standardized self-report questionnaire measuring difficulty identifying, describing, and processing emotions. The Toronto Alexithymia Scale (TAS-20) is the most validated instrument, comprising 20 items scored to yield a total alexithymia score and three subscale scores.
How long does the alexithymia test take?
Most patients complete the TAS-20 in 5-10 minutes. The longer OAQ-G2 (37 items) requires 10-15 minutes. Time varies based on reading speed and reflection depth.
Can the alexithymia test diagnose autism?
No. The alexithymia test measures emotion-identification difficulty, not autism. Alexithymia and autism are distinct but may co-occur. Autism diagnosis requires formal developmental history, communication assessment, and specialist evaluation.
Is a high alexithymia test score treatable?
Yes. Evidence-based interventions include emotion-labeling exercises, somatic therapy, mindfulness, and narrative approaches. Serial testing tracks improvement in emotional awareness over therapy episodes.
What are the two types of alexithymia?
Clinicians often distinguish primary (trait) alexithymia, a stable feature likely rooted in development or neurobiology, from secondary (state) alexithymia, which is acquired in response to trauma, chronic illness, or acute stress and can ease as the underlying cause is treated.
What is the difference between alexithymia and depression?
Depression is a mood disorder with low mood, anhedonia, and hopelessness. Alexithymia is a difficulty processing emotions independent of mood state. Alexithymia often co-occurs with depression and complicates treatment engagement.
How can I know if I have alexithymia?
The clearest first step is to complete a validated test for alexithymia, most often the 20-item Toronto Alexithymia Scale. A total score of 61 or higher points to clinically significant alexithymia, and 52 to 60 is borderline. Because the questionnaire is a screen rather than a diagnosis, discuss an elevated score with a mental health clinician who can confirm it alongside a clinical interview.
Can people with alexithymia cry?
Yes. Alexithymia is difficulty identifying and describing emotions, not an absence of emotion or physical responses. Someone with alexithymia can cry, laugh, or feel physiological arousal, yet struggle to name what they are feeling or link it to a cause. That gap between a bodily reaction and an emotional label is what the assessment measures.
Do doctors believe that alexithymia is real?
Alexithymia is a well-researched, widely accepted construct, even though it is not a standalone diagnosis in the DSM-5. It is measured with validated instruments like the TAS-20 and studied across depression, anxiety, autism, and somatic conditions, so clinicians treat it as a meaningful trait that shapes how a patient engages with care.
